While it is universally true much more attention is focused on success in clinical trials in the sense of patients who respond well to a particular therapy, this doesn’t mean we can’t learn from people who tumours either don’t respond to treatment up front or relapse early.
In our latest review, we look at three different examples of what we can learn from biomarkers of T cell exhaustion with both CAR-T cell therapies (with two different targets) as well as immune checkpoint blockade.
In short, there’s more to think about beyond antigen loss and target downregulation.
Why does this matter?
Well if we can identify markers of early relapse then we can either intervene earlier and switch to another therapy or we can add something else in to try and rescue the patient’s immune response.
Here we discuss some of the scientific findings from different research labs and explore how the information uncovered may be key to either future novel developments or clinical strategies with current immunotherapy approaches…
To learn more from our oncology analysis and get a heads up on the latest insights and commentary, subscribers can log-in or you can click to gain access to BSB Premium Content.
Over the last five years we have followed the trials and tribulations of CAR T cell therapies in ALL and aggressive lymphomas as Novartis, Kite, Juno, Cellectis, Unum and others have undertaken the road less travelled towards filing and approval.
The ASH DASH in action!
Now that we have seen the first two CAR T cell approvals in pediatric ALL (Novartis) and aggressive lymphomas (Kite), with tisagenlecleucel widely expected to be the next one in aggressive lymphomas following presentation of the 6-month JULIET data at the recent American Society of Hematology (ASH) meeting in Atlanta, a key question remains to be addressed:
Is there a threat on the horizon that might be potentially used prior to CAR T cell therapy in refractory lymphomas?
We say ‘yes, there is’ and thus it was interesting to see where this approach might go… including discussion with an expert.
To learn more and get a heads up on our latest insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
And we’re off on the infamous ASH DASH…
Atlanta Centennial Olympic Park
The annual data drop for the American Society of Hematology (ASH) meeting in Atlanta, Georgia is finally here.
Each year we write a series of in-depth previews ahead of the event exploring different aspects of hematologic malignancies in terms of what’s important, what to watch out for, and also key abstracts that may (or may not) have an impact.
This year we kick off the first of our series with a look at aggressive lymphomas and novel therapies in development including CAR T cell therapies, antibodies, ADCs and targeted therapies. There are some surprsies (of course) and also some potentially interesting relationships and consequences to consider.
To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.
One of the intriguing themes that emerged recently at ASCO from several cancer immunotherapy trials centred around whether any elicited immune responses actually correlated with outcomes and if so, why and how?
Gems from the ASCO17 poster hall
It sounds easy in practice, yet in reality the topic has been quite a controversial one that has been hotly debated for a while.
With a wealth of new cancer immunotherapy trials now undwerway and initial results trickling out, how do we start to make sense of the information and what do we learn that might be useful going forward for future trials and the field as a whole?
With the help of a renowned cancer immunologist, we explored this concept in more detail to determine what can be gleaned from the data available.
Today, we look at part one of our latest mini-series, with the second part to follow later this week.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.
Yesterday Novartis announced the initial data from the JULIET trial in relapsed/refractory aggressive lymphomas such as diffuse large cell lymphomas (DLBCL) that were presented at the upcoming International Conference on Malignant Lymphoma (iCML) meeting in Lugano.
Here at BSB, we’ve been following CAR T cell therapy developments in earnest since 2012 when Penn and Novartis first announced their collaboration to develop what is now known as CTL019.
Five years on, we now have two such cell therapy products already filed with the Health Authorities and the JULIET trial will likely be the third indication submitted by the end of the year. This niche is now well established for regular readers and not something that has been a flash in the pan over a year or so.
There are a few interesting points of note on the CAR T cell front that are also worth exploring in conjunction with this news.
Subscribers can login to read our latest insights or you can purchase access to BSB Premium Content.
Although ASH and ASGCT are important meetings for CAR T cell therapies, there are still some intriguing data to be had at ASCO next month, including both oral and poster abstracts.
In our latest ASCO 2017 Preview, we take a look at what to expect from in the CAR T cell space.
Subscribers can login to read our latest insights and analysis
We’re overdue a roundup and discussion on various key topics of interest to BSB readers, so here goes…
Today’s topics include an in-depth look at the impact of some negative events:
- Kite and the cerebral oedema death with axi-cel
- Genentech’s atezolizumab OS miss in urothelial cancer
Subscribers can login to read our latest expert interview
It’s finally time…
US Capitol Building, DC
By popular request from BSB readers, we have a CAR T cell therapy preview of the main abstracts to watch out for, including talks and posters, and what emerging themes to expect are likely to be.
If you are registered on the AACR site and signed in, then clicking on any of the abstracts highlighted in this review will enable you to add any interesting ones you fancy to your conference itinerary.
There’s a surprising amount to cover this year, especially when we consider the incredible work that’s ongoing to address a number of suboptimal aspects in the construct developments. It’s continuing to progress at warp speed, so hold onto your hats and buckle down for our latest rock around the AACR clock.
Subscribers can log in to learn more…